吗啡药物市场规模 - 按剂型（注射、口服）、应用（疼痛管理 [癌症、神经性、骨关节炎]、安宁疗护、止泻药、感冒和咳嗽、麻醉）、配销通路、最终用途和预测，2024年 - 2032

2024年至2032年，全球吗啡药物市场复合年增长率将超过6.5%。随着安宁疗护服务在全球扩展，吗啡成为管理临终疼痛和提高病患生活品质的基石。它在减轻剧烈疼痛方面的功效使其成为为末期病人提供舒适和缓解所不可或缺的。对安宁疗护的日益重视凸显了疼痛管理在医疗保健中的重要性。它增加了对吗啡等易于使用且有效的鸦片类药物的需求，确保全球患者获得有尊严和富有同情心的临终关怀。

市场竞争格局的特点是几家主要的吗啡药品生产商专注于药品生产和分销。普渡製药 (Purdue Pharma)、强生 (Johnson & Johnson) 和 Mallinckrodt Pharmaceuticals 等公司凭藉其广泛的产品组合和全球市场覆盖率在市场上占据主导地位。这些製造商根据产品效率、法规遵守情况、安全性和药物传输技术的发展进行竞争，以满足医疗保健供应商和患者需要疼痛管理解决方案的需求。

整个吗啡药物市场根据剂型、配销通路、应用、最终用途和地区进行分类。

到 2032 年，口腔领域的复合年增长率将出现显着的增长。此外，全球慢性疼痛的盛行率不断上升，也刺激了口服吗啡製剂的处方率提高。此外，医疗保健提供者对口服吗啡在平衡疼痛缓解和患者安全方面的好处的认识不断提高，促使其在临床实践中得到越来越多的采用，从而增加了口服药物领域的需求。

到 2032 年，安宁疗护领域将在吗啡药物市场占据重要份额，因为它在治疗与末期疾病相关的严重疼痛方面发挥着至关重要的作用。随着安宁疗护在改善末期疾病的生活品质方面获得认可，吗啡在减轻疼痛和增强舒适度方面的功效已变得不可或缺。医疗保健提供者越来越依赖吗啡来减轻身体痛苦，以确保有尊严的临终关怀。不断发展的医疗政策和指南强化了这一趋势，这些政策和指南优先考虑将疼痛管理作为整体患者护理的一个组成部分，从而推动了安宁疗护中对吗啡的需求。

到 2032 年，亚太地区吗啡药物市场的复合年增长率将保持乐观。此外，亚太地区医疗基础设施的改善和医疗支出的增加正在促进更多人获得止痛药。随着该地区对安宁疗护的认识不断提高，人们越来越多地接受和采用吗啡作为管理临终疼痛和改善患者舒适度的重要组成部分，从而增加了其需求。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 慢性疼痛的盛行率不断增加
    • 安宁疗护意识不断增强
    • 药物製剂技术进步
    • 外科手术数量不断增加
  • 产业陷阱与挑战
    • 不良反应和过量的风险
    • 对阿片类药物成瘾和滥用的担忧
• 成长潜力分析
• 监管环境
• 管道分析
• 波特的分析
• PESTEL分析
• 未来市场趋势

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按剂型，2021 - 2032

• 主要趋势
• 可注射
• 口服
• 其他剂型

第 6 章：市场估计与预测：按应用分类，2021 - 2032

• 主要趋势
• 疼痛管理
  • 癌症痛
  • 神经性疼痛
  • 骨关节炎疼痛
  • 其他疼痛管理
• 安宁疗护
• 止泻药
• 麻醉
• 感冒止咳药
• 其他应用

第 7 章：市场估计与预测：按配销通路划分，2021 - 2032 年

• 主要趋势
• 医院药房
• 零售药房
• 网路药房

第 8 章：市场估计与预测：按最终用途，2021 - 2032 年

• 主要趋势
• 医院和诊所
• 门诊手术中心
• 其他最终用户

第 9 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 10 章：公司简介

• Alcaliber S.A.
• Daiichi Sankyo Company Limited
• Hikma Pharmaceuticals PLC
• Mallinckrodt plc
• Pfizer Inc.
• Purdue Pharma L.P.
• Sandoz AG
• Taj Pharmaceuticals Limited
• Verve Health Care Ltd.
• Viatris Inc.

Global Morphine Drugs Market will witness over 6.5% CAGR from 2024 to 2032. Morphine's pivotal role in palliative care significantly spurs the demand. As palliative care services expand globally, morphine emerges as a cornerstone in managing end-of-life pain and enhancing patients' quality of life. Its efficacy in alleviating severe pain makes it indispensable in providing comfort and relief for terminally ill individuals. This growing emphasis on palliative care highlights the importance of pain management in healthcare. It amplifies the need for accessible and effective opioid medications like morphine, ensuring dignified and compassionate end-of-life care for patients globally.

The competitive landscape in the market is characterized by several key morphine drug producers focusing on pharmaceutical production and distribution. Companies such as Purdue Pharma, Johnson & Johnson, and Mallinckrodt Pharmaceuticals dominate the market with their extensive product portfolios and global market reach. These manufacturers compete based on product efficiency, regulatory adherence, safety profiles, and developments in drug delivery technologies to meet the demands of healthcare vendors and patients requiring pain management solutions.

The overall morphine drugs market is classified based on dosage form, distribution channel, application, end-use, and region.

The oral segment will experience prominent CAGR expansion through 2032. Advancements in oral drug delivery technology have enhanced the efficacy and convenience of administering morphine, making it more accessible for patients requiring long-term pain management. Additionally, the increasing prevalence of chronic pain conditions globally has spurred greater prescription rates for oral morphine formulations. Moreover, heightened awareness among healthcare providers about the benefits of oral morphine in balancing pain relief and patient safety has contributed to its growing adoption in clinical practice, escalating its demand in the oral drug segment.

The palliative care segment will garner a significant morphine drugs market share by 2032, owing to its crucial role in managing severe pain associated with terminal illnesses. As palliative care gains recognition for improving the quality of life in end-stage diseases, morphine's effectiveness in alleviating pain and enhancing comfort has become indispensable. Healthcare providers increasingly rely on morphine to ensure dignified end-of-life care by providing relief from physical suffering. This trend is reinforced by evolving healthcare policies and guidelines that prioritize pain management as an integral component of holistic patient care, driving the demand for morphine in palliative settings.

The CAGR for the Asia Pacific morphine drugs market will be optimistic through 2032. Increasing incidences of chronic diseases and cancer-related pain are ushering in the need for effective pain management solutions like morphine. Moreover, improvements in healthcare infrastructure and rising healthcare expenditures in the Asia Pacific are facilitating greater access to pain relief medications. As awareness about palliative care increases in the region, there is a growing acceptance and adoption of morphine as a crucial component in managing end-of-life pain and improving patient comfort, boosting its demand.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of chronic pain conditions
    • 3.2.1.2 Growing awareness of palliative care
    • 3.2.1.3 Technological advancements in drug formulations
    • 3.2.1.4 Rising number of surgical procedures
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Risk of adverse effects and overdose
    • 3.2.2.2 Concerns about opioid addiction and abuse
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis
• 3.8 Future market trends

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Injectable
• 5.3 Oral
• 5.4 Other dosage forms

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Pain management
  • 6.2.1 Cancer pain
  • 6.2.2 Neuropathic pain
  • 6.2.3 Osteoarthritis pain
  • 6.2.4 Other pain managements
• 6.3 Palliative care
• 6.4 Diarrhea suppressant
• 6.5 Anesthesia
• 6.6 Cold & cough suppressant
• 6.7 Other applications

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacy
• 7.3 Retail pharmacy
• 7.4 Online pharmacy

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals and clinics
• 8.3 Ambulatory surgical centers
• 8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Alcaliber S.A.
• 10.2 Daiichi Sankyo Company Limited
• 10.3 Hikma Pharmaceuticals PLC
• 10.4 Mallinckrodt plc
• 10.5 Pfizer Inc.
• 10.6 Purdue Pharma L.P.
• 10.7 Sandoz AG
• 10.8 Taj Pharmaceuticals Limited
• 10.9 Verve Health Care Ltd.
• 10.10 Viatris Inc.